Pre-emptive targeting of the epitope spreading cascade with genetically modified regulatory T cells during autoimmune demyelinating disease

被引:10
作者
Yin, L [1 ]
Yu, M [1 ]
Edling, AE [1 ]
Kawczak, JA [1 ]
Mathisen, PM [1 ]
Nanavati, T [1 ]
Johnson, JM [1 ]
Tuohy, VK [1 ]
机构
[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA
关键词
D O I
10.4049/jimmunol.167.11.6105
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Epitope spreading or endogenous self-priming has been implicated in mediating the progression of autoimmune disease. In the present study we created an immune-deviated, epitope spreading response in SWXJ mice after the onset of experimental autoimmune encephalomyelitis, a prototypic autoimmune animal model widely used in multiple sclerosis research. We established an immunoregulatory spreading repertoire by transferring T cells genetically modified to produce high levels of IL-10 in response to a dominant epitope spreading determinant. Installation of a Th2/Tr1-like spreading repertoire resulted in a marked and prolonged inhibition of disease progression and demyelination characterized by 1) bystander inhibition of the recall response to the priming immunogen, and 2) a Th1 --> Tr1 immune-deviated spreading response involving a shift in the source of IL-10 production from the transferred regulatory population to the host-derived, endogenously primed repertoire. Thus, our data provide a rationale for cell-based therapeutic intervention in multiple sclerosis by showing that pre-emptive targeting of the epitope spreading cascade with regulatory T cells effectively induces an immune-deviated spreading response capable of inhibiting ongoing inflammatory autoreactivity and disease progression.
引用
收藏
页码:6105 / 6112
页数:8
相关论文
共 39 条
[31]   Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system [J].
Steinman, L .
CELL, 1996, 85 (03) :299-302
[32]   ANIMAL-MODELS OF HUMAN-DISEASE - EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS IN RODENTS AS A MODEL FOR HUMAN DEMYELINATING DISEASE [J].
SWANBORG, RH .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 77 (01) :4-13
[33]   Relapsing and remitting experimental allergic encephalomyelitis: a focused response to the encephalitogenic peptide rather than epitope spread [J].
Takacs, K ;
Chandler, P ;
Altmann, DM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (11) :2927-2934
[34]  
TIBERGHIEN P, 1994, BLOOD, V84, P1333
[35]   Axonal transection in the lesions of multiple sclerosis [J].
Trapp, BD ;
Peterson, J ;
Ransohoff, RM ;
Rudick, R ;
Mörk, S ;
Bö, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05) :278-285
[36]   Immunobiology of interleukin-12 [J].
Trinchieri, G .
IMMUNOLOGIC RESEARCH, 1998, 17 (1-2) :269-278
[37]   Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis [J].
Tuohy, VK ;
Yu, M ;
Yin, L ;
Kawczak, JA ;
Kinkel, RP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (07) :1033-1042
[38]   IMMUNIZATION WITH A SYNTHETIC T-CELL RECEPTOR V-REGION PEPTIDE PROTECTS AGAINST EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS [J].
VANDENBARK, AA ;
HASHIM, G ;
OFFNER, H .
NATURE, 1989, 341 (6242) :541-544
[39]   A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease [J].
Yu, M ;
Johnson, JM ;
Tuohy, VK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (04) :1777-1788